Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortalityPooled absolute risk reduction of 8.3%; Relative risk reduction of 18%Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit38.7%…